A current hot topic in COPD is that two "fixed triple" combinations of an inhaled corticosteroid (ICS), a long-acting β~2~-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) in a single inhaler have become available for patients with COPD, and a third triple therapy is in advanced development with the first large randomised clinical trial (RCT) recently published in *Lancet Respiratory Medicine* \[[@C1]\]. The triple therapies available in a single inhaler are: beclomethasone-dipropionate/formoterol/glycopyrronium (BDP/FF/G); fluticasone-furoate/vilanterol/umeclidinium (FLF/VI/UMEC); and budesonide/glycopyrronium/formoterol (B/G/F).

Whether triple therapy in a single inhaler outperforms the three individual components given in separate inhalers is unknown. In fact, there is only one study where the triple therapy in a single inhaler was compared to triple therapy in separate inhalers, but the LAMA was different with glycopyrronium in the former (BDP/FF/G) and tiotropium in the latter. The two triple therapies were equally effective, and both superior to tiotropium alone \[[@C2]\].

For the time being, the additional benefit of a fixed triple LABA/LAMA/ICS combination is related to convenience for the patient, and possibly improved compliance. However, we may speculate that the simultaneous delivery to the target organ of three agents with different mechanisms of action may improve positive interactions between them. In addition, triple therapy might improve activity levels through bronchodilation or reduced breathlessness, and thereby improve respiratory muscle strength and impact upon disease progression.

FLF/VI/UMEC is approved in the European Union as a maintenance treatment in adult patients with moderate-to-severe COPD who are not adequately treated by a combination of an ICS/LABA or LABA/LAMA, whereas BDP/FF/G is approved only for patients not controlled by LABA/ICS combination (the approval in addition to LABA/LAMA is pending). In the USA, only FLF/VI/UMEC is approved, both for the long-term, maintenance treatment of airflow obstruction in patients with severe COPD and to reduce exacerbations of COPD in patients with a history of exacerbations. These slightly different indications have in common that triple therapy is recommended for patients not adequately controlled by existing inhaled combination therapies. Neither the European Medicines Agency (EMA) nor the US Food and Drug Administration (FDA) make a distinction between initiation of therapy in untreated newly diagnosed patients, *versus* use of triple therapy in already treated patients, as both assume triple therapy is a step-up. The position proposed by the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document \[[@C3]\] recommends triple therapy only as a step-up from LAMA/LABA or ICS/LABA in patients whose disease is not adequately controlled by one of these two combinations. While the positioning of the triple therapy recommended by GOLD, and by the FDA and EMA, is straightforward, the published evidence on which these recommendations are based suggest that there are other conditions in which triple might be considered or not recommended.

Several reviews and editorials have been already published on triple therapy in COPD \[[@C4]--[@C9]\], but none of them address the issues related to the possible use of triple therapy in real life, possibly outside of the strict indications reported by the registration agencies, or when triple therapy should not be considered at all even when recommended.

As members of a specialised hospital-based "COPD Centre", we thought that a short commentary "thinking outside the box" on the potential practical use (or non-use) of triple therapy might provide a stimulating tool for discussion in the pulmonary community.

Possible use of triple therapy outside of the recommendations {#s1}
=============================================================

1\) While the strongest part of the evidence for triple therapy is based on results on exacerbations, in individual patients the change of treatment is most frequently based on symptoms. Indeed, the SPIROMICS study showed that in subjects with GOLD stage 1 and 2 COPD, the prevalence of the use of ICS and bronchodilators was 22% and 39% in those with low symptoms (COPD Assessment Test (CAT) \<10) and 46% and 67% in those with high symptoms (CAT \>10) \[[@C10]\]. It has been shown in real-life analysis that 32% of all patients with a diagnosis of COPD in primary care end up with triple therapy within 1 year of diagnosis \[[@C11]\]. This inevitable drift to triple therapy is almost invariably due to a limited effect of any regular treatment for COPD (LABA, LAMA, LABA/LAMA, LABA/ICS and even triple therapy) on both symptoms and use of rescue medication. Thus, individual patients are highly likely to be overtreated in order to increase such a limited effect. This suggests that a trial with triple therapy will be almost invariably be tried "*ex juvantibus*" in every patient even without a risk of exacerbation, who remain highly symptomatic on LAMA, LABA/LAMA or LABA/ICS. In this case, a step-down should be strongly recommended if after 1--3 months patients do not report improvement of symptoms.

2\) Patients with a rapid decline in lung function. Previous large studies have clearly shown that ICS alone does not alter lung function decline in patients with COPD \[[@C12]--[@C15]\]. However, there is increasing amount of more recent literature that supports a role for ICS combined with bronchodilators suggesting an effect on lung function decline. In a *post hoc* analysis of UPLIFT \[[@C16]\], a modest reduction in decline was seen in patients on LAMA (but of note a high proportion of included subjects were on ICS \[[@C17]\]). In a *post hoc* analysis of TORCH \[[@C12]\], ICS combined with LABA was shown to slow down the decline in lung function \[[@C17]\]. The ICS/LABA effect has been confirmed in a recent large long-term prospective study conducted in moderate COPD patients with increased cardiovascular risk. Indeed, even if the study failed in showing a significant effect on survival (primary outcome), it demonstrated a decrease of lung function decline with no increase of pneumonia in patients treated with LABA/ICS *versus* patients treated with LABA alone \[[@C18], [@C19]\]. In addition, the WISDOM study showed no increase in exacerbation risk but a significant decline in lung function when ICS was withdrawn in COPD patients treated with triple LABA/LAMA/ICS \[[@C20]\].

In a *post hoc* analysis of the FULFIL study, only 25% of those on FF/UMEC/VI, compared with 56% of those on budesonide/formoterol (BUD/FOR), experienced a clinical meaningful decline in lung function of \>100 mL in the intention to treat population during the 26 weeks study period, suggesting that the triple FF/UMEC/VI therapy may significantly reduce the risk of clinically important deterioration *versus* twice daily BUD/FOR with a five-fold longer period without deterioration \[[@C21]\]. Finally, it seems that an accelerated decline in lung function is particularly the case in those COPD patients with self-reported late-onset asthma \[[@C22]\]. In the light of the above evidence retrieved from the literature, we suggest considering triple therapy COPD patients who present with a significant lung function decline.

3\) All six studies supporting triple therapy included COPD patients with a history of asthma, even if they excluded subjects with active asthma \[[@C1], [@C2], [@C23]--[@C26]\]. We believe that all symptomatic COPD patients with a history of asthma and/or current asthma, or concomitant traits characteristic for the presence of asthma as described earlier \[[@C27]\], should be considered for triple therapy if not adequately controlled by LABA/ICS and in any case should not be treated with long-acting bronchodilators without ICS. In individual cases, even higher doses of ICS then commonly used in COPD might be appropriate.

4\) Concerning patients with asthma, the most recent 2018 Global Initiative for Asthma strategy document recommends adding tiotropium to patients with asthma who have airflow limitation even when treated with LABA/ICS combination \[[@C28]\]. None of the five studies with a triple therapy combination in a single inhaler included tiotropium; however, V[estbo]{.smallcaps} *et al*. \[[@C2]\] showed equivalence between BDP/FF/G and tiotropium plus BDP/FF in a separate inhaler in COPD, thus it is reasonable to predict that triple combination in a single inhaler will be frequently used in symptomatic asthma patients with persistent airflow limitation who would require additional bronchodilatation with a LAMA. RCTs testing triple therapy in severe asthma are ongoing, and the results will be available soon (*e.g*. the TRIGGER Study, [ClinicalTrials.gov](ClinicalTrials.gov) identifier: NCT02676089).

5\) Most of the evidence collected, to date, with triple therapy in a single inhaler included patients with moderate-to-very severe airflow limitation with increased risk of exacerbations suggested by at least one (not two) moderate exacerbations per year while receiving LAMA, LABA/LAMA or LABA/ICS. Thus, we believe that these criteria should be used with confidence in clinical practice, maybe limiting to one rather than two the number of exacerbations in the previous year as a risk factor for future exacerbations to be used for prescription of regular triple therapy \[[@C29]\]. Indeed, studies on large cohorts showed that patients with one compared with no exacerbation in the previous year had a more than twofold increased risk for experiencing an exacerbation in the next year \[[@C30], [@C31]\]. Then again, the most recent study on triple therapy (KRONOS) was effective in reducing exacerbations even in symptomatic patients without history of exacerbation as the inclusion criterium (70% of patients had no exacerbations in the previous year) \[[@C1]\]. Additional tools to predict exacerbation risk and treatment response and establish the risk/benefit ratio are needed. Eosinophil counts might help to fulfil this need \[[@C32]\]. This concept has been adopted by the most recent update of the GOLD strategy document, which has also introduced the criteria of 100--300 blood eosinophils·µL^−1^ for considering ICS and of \>300 blood eosinophils·µL^−1^ for recommending an ICS containing combination \[[@C3]\].

6\) Even without any evidence, just as an expert opinion deriving from clinical practice, we believe that there are two other conditions where triple therapy may be considered as first choice and not as a step-up. First, in the patient discharged from the hospital after an acute exacerbation of COPD, and in whom COPD is diagnosed for the first time because of the severe exacerbation. These patients are commonly given the usual treatment with inhaled bronchodilators (mostly continuous short-acting β~2~-agonists and short-acting muscarinic antagonists as nebulised therapy), systemic steroids and antibiotics during their hospitalisation, and are at high risk of re-hospitalisation particularly during the first month \[[@C33], [@C34]\]. We suggest that these rare cases could be put on maintenance therapy at least for the first 1--3 months and then narrowly considered for step-down ([figure 1](#F1){ref-type="fig"}).Second, in patients who present for the first time, and are diagnosed with severe airway obstruction (forced expiratory volume in 1 s \<50%), are symptomatic, had frequent moderate (≥2) or severe exacerbations (≥1 hospitalisation) in the previous year, and have peripheral eosinophilia (\>300 cells·µL^−1^), *i.e.* patients at high risk of recurrent exacerbations and/or hospitalisation \[[@C33], [@C35]--[@C37]\]. Also, for these patients we would recommend to put them on maintenance therapy with triple therapy at least for the first 3 months and then consider a step-down ([figure 1](#F1){ref-type="fig"}).

![Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). We suggest an initial treatment for the patient as a function of the first presentation and correct COPD diagnosis. The majority of patients will not receive triple therapy at first presentation, but depending their natural history might end up escalating to triple therapy. Patients who present for the first time with hospitalisation or high symptoms and high exacerbation risk could be considered for triple therapy, which is then re-evaluated during follow up. LAMA: long-acting muscarinic antagonist; LABA: long-acting β~2~-agonist; ICS: inhaled corticosteroid.](00185-2018.01){#F1}

Patients with COPD not to treat with triple therapy {#s2}
===================================================

1\) All studies performed, to date, with triple therapy have included symptomatic patients, *i.e.*patients with either CAT ≥10 and/or modified Medical Research Council ≥2. We see no reason with the evidence available at this point to consider triple therapy for asymptomatic patients, unless the patient fulfils point 2, 3 or 4 outlined in the previous section and has few symptoms in between exacerbations.

2\) Similarly, even if symptomatic smokers with normal lung function or restrictive impairment may in fact have a similar risk of exacerbations as symptomatic smokers with obstructive impairment \[[@C10]\], we see no reason with the evidence available at this point to consider triple therapy for symptomatic patients without airflow limitation.

3\) While the recent studies with triple therapy in a single inhaler suggest an effect on survival after 1 year of treatment \[[@C25], [@C38]\], this effect was observed only on a moderate to severe population of symptomatic patients at risk of exacerbations, and survival was not a predefined outcome Thus, until a properly designed study is performed and is positive on this outcome, triple therapy should not be considered to improve survival in COPD patients

4\) The most recent triple therapy study included symptomatic COPD patients with moderate-to-very severe airflow limitation without a history of exacerbations in the previous year, had a duration of 6 months and was powered on lung function and no patient-related outcome (PRO) (*e.g.* exacerbation) \[[@C1]\]. Although the study showed superiority of triple over dual combinations not only on lung function but also on relevant secondary PROs (*e.g.* symptoms and exacerbations), without safety concerns, we usually need at least two consistent RCTs on a clinically relevant primary outcome before issuing recommendations. Thus, we believe that triple therapy should not be recommended as regular treatment for patients without a history of exacerbations in the previous year.

5\) COPD and eosinopenia. There is evidence to suggest that the effect of ICS on COPD exacerbations increases with the number of circulating eosinophils, and that they are ineffective in patients with low blood eosinophils (50--100 cells·µL^−1^ \[[@C26], [@C35], [@C39]\]), and that eosinopenia increases the risk of pneumonia \[[@C40], [@C41]\]. For these reasons, unless strictly necessary because either bronchodilators are not sufficient, or there is a history of active severe uncontrolled asthma, we would not recommend the use of ICS, including triple therapy, in patients with \<100 eosinophils·µL^−1^.

6\) Patients with COPD are at increased risk of infections, particularly pneumonia, bronchiectasis, tuberculosis and even non-tuberculous mycobacterial infections \[[@C3]\]. Patients with COPD at risk of recurrent pneumonias with or without bronchiectasis, patients with bronchiectasis and recurrent respiratory infections, and patients with active tuberculosis should be not be treated with ICS, including triple therapy, and if ICS are strictly required, they should be carefully monitored for the risk of infection.

7\) Patients with HIV treated with antiretroviral therapy (ARVs) often present with COPD \[[@C42]\], which is sometimes severe. ICS should not be co-administered in HIV patients on an ARV-boosted regimen due to the strong inhibition of their metabolism, which increases the risk of Cushing\'s syndrome, particularly fluticasone and budesonide. Only beclomethasone dipropionate may be considered, if strictly needed, but with careful monitoring of drug dosage or timing of administration \[[@C43]\].

8\) Similarly, in clinical practice, we should be careful in considering individual or combined bronchodilator components (LABA and/or LAMA) or triple therapy in severe multimorbid COPD patients (particularly severe arrhythmias, severe heart failure and/or ischaemic heart disease, stroke, transient ischaemic attacks, *etc.*) in whom the efficacy/safety of these agents have not been tested \[[@C44]--[@C46]\].

Conclusions {#s3}
===========

Triple therapy should not be applied to most patients diagnosed with COPD as the majority have low symptoms and low exacerbation risk \[[@C47]\] and can be controlled with non-pharmacological interventions and bronchodilators only ([figure 1](#F1){ref-type="fig"}). However, those who remain symptomatic even during maintenance treatment with bronchodilators or had a moderate-to-severe exacerbation in the previous year, persistent accelerated decline in lung function or those having a previous diagnosis of asthma or overlapping characteristics with asthma, might in our opinion be candidates for at least a trial with triple therapy, although this is not compliant with GOLD, EMA or FDA recommendations. By contrast, triple therapy should not be considered in asymptomatic subjects regardless of the degree of airflow limitation, in subjects without a correct diagnosis, or in subjects at high risk of complications linked to its components, particularly the ICS.

We realise that some of our suggestions derive from clinical practice and are not supported by evidence, and thus that the effects to be expected are unknown and might be disproved by future studies. However, as often happens in medicine, we hope that our suggestions might be of some help for individual patients who do not meet the criteria recommended by the current documents \[[@C3]\].
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